CN1981043B - 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用 - Google Patents

用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用 Download PDF

Info

Publication number
CN1981043B
CN1981043B CN200580015744XA CN200580015744A CN1981043B CN 1981043 B CN1981043 B CN 1981043B CN 200580015744X A CN200580015744X A CN 200580015744XA CN 200580015744 A CN200580015744 A CN 200580015744A CN 1981043 B CN1981043 B CN 1981043B
Authority
CN
China
Prior art keywords
protein
virus
gly
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200580015744XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1981043A (zh
Inventor
菲利普·德普雷斯
皮埃尔·沙尔诺
弗雷德里克·坦吉
马里-帕斯卡莱·弗伦凯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut Pasteur
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Institut Pasteur filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN1981043A publication Critical patent/CN1981043A/zh
Application granted granted Critical
Publication of CN1981043B publication Critical patent/CN1981043B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200580015744XA 2004-05-17 2005-05-16 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用 Expired - Lifetime CN1981043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0405366 2004-05-17
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
PCT/IB2005/001753 WO2005111221A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Publications (2)

Publication Number Publication Date
CN1981043A CN1981043A (zh) 2007-06-13
CN1981043B true CN1981043B (zh) 2010-06-09

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580015744XA Expired - Lifetime CN1981043B (zh) 2004-05-17 2005-05-16 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用

Country Status (9)

Country Link
US (2) US20090214589A1 (https=)
EP (2) EP1751291B1 (https=)
JP (1) JP2008508863A (https=)
CN (1) CN1981043B (https=)
BR (1) BRPI0510016B8 (https=)
CA (1) CA2564934C (https=)
FR (1) FR2870126B1 (https=)
MX (1) MXPA06013388A (https=)
WO (1) WO2005111221A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108040484A (zh) * 2014-12-11 2018-05-15 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US20110262472A1 (en) * 2008-04-22 2011-10-27 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP2603799A4 (en) 2010-08-12 2014-02-12 Clontech Lab Inc SIDEFLOW ASSAYS FOR NON-DIAGNOSTIC ANALYSIS
WO2017083291A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
SG11202004234SA (en) 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087915A (zh) * 1992-07-16 1994-06-15 东燃株式会社 用于丙型肝炎病毒分类的抗原肽,含有所述肽的药盒及用所述肽进行分类的方法
CN1379820A (zh) * 1999-10-11 2002-11-13 巴斯德研究所 用于制备免疫治疗性组合物的慢病毒载体
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU4554899A (en) 1998-06-09 1999-12-30 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
FR2794865B1 (fr) 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
EP1092780A1 (en) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Recombiant, replication defective CELO virus and CELO virus DNA
CA2443290C (fr) 2001-04-04 2011-11-08 Institut Pasteur Souche neurovirulente du virus west-nile et ses applications
US20040037848A1 (en) 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
CA2903126C (en) 2002-01-10 2020-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
DE10249594A1 (de) * 2002-10-24 2004-05-13 Jassoy, Christian, Dr. Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
CA2456873A1 (en) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087915A (zh) * 1992-07-16 1994-06-15 东燃株式会社 用于丙型肝炎病毒分类的抗原肽,含有所述肽的药盒及用所述肽进行分类的方法
US20030104611A1 (en) * 1998-01-16 2003-06-05 Johnston Julie C. Feline immunodeficiency virus gene therapy vectors
CN1379820A (zh) * 1999-10-11 2002-11-13 巴斯德研究所 用于制备免疫治疗性组合物的慢病毒载体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jan-Jong Hung et al..An External Loop Region of Domain III of Dengue Virus Type2 Envelope Protein Is Involved in Serotype-Specific Bindingto Mosquito but Not Mammalian Cells.Journal of Virology78 1.2004,78(1),图1A.
Jan-Jong Hung et al..An External Loop Region of Domain III of Dengue Virus Type2 Envelope Protein Is Involved in Serotype-Specific Bindingto Mosquito but Not Mammalian Cells.Journal of Virology78 1.2004,78(1),图1A. *
同上.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108040484A (zh) * 2014-12-11 2018-05-15 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物
CN108040484B (zh) * 2014-12-11 2022-04-26 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物

Also Published As

Publication number Publication date
EP1751291B1 (en) 2013-07-31
BRPI0510016B1 (pt) 2020-03-10
CN1981043A (zh) 2007-06-13
US20090214589A1 (en) 2009-08-27
BRPI0510016A (pt) 2007-09-18
MXPA06013388A (es) 2007-06-19
WO2005111221A1 (en) 2005-11-24
CA2564934A1 (en) 2005-11-24
FR2870126A1 (fr) 2005-11-18
BRPI0510016B8 (pt) 2021-05-25
EP1751291A1 (en) 2007-02-14
EP2371966B1 (en) 2015-11-25
US8716013B2 (en) 2014-05-06
EP2371966A1 (en) 2011-10-05
JP2008508863A (ja) 2008-03-27
US20110206710A1 (en) 2011-08-25
CA2564934C (en) 2014-07-08
FR2870126B1 (fr) 2009-07-17

Similar Documents

Publication Publication Date Title
US8716013B2 (en) Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
ES2535310T3 (es) Atenuación sinérgica del virus de la estomatitis vesicular, vectores del mismo y composiciones inmunogénicas del mismo
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
AU2006310173B2 (en) A lentiviral vector-based vaccine
US6455509B1 (en) Dengue nucleic acid vaccines that induce neutralizing antibodies
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
CN102711817B (zh) 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物
Brandler et al. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines
WO2014093602A1 (en) Compositions and methods for treating and preventing hepatitis c virus infection
EP2020444B1 (en) Defective non-integrative lentiviral transfer vectors for vaccines
US8222029B2 (en) Lentiviral vector-based vaccine
ES2410593T3 (es) Ácidos nucleicos y polipéptidos de lisavirus quiméricos
US20030124146A1 (en) Recombinant Rhabdoviruses as live-viral vaccines
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
Timpona VSV vectors as vaccines for emerging viruses and as probes for entry pathways
Iyer Phylogenetics and New Approaches to Vaccine Development for West Nile
TW201002343A (en) Flavivirus NS1 subunit vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100609